<DOC>
	<DOC>NCT00143728</DOC>
	<brief_summary>The purpose of this study is to compare the effects of continuing or discontinuing 3TC treatment in the presence of HIV virus with 3TC resistance for persons who are on a regimen including least three other anti-HIV drugs. The overall aim is to determine whether continuing 3TC is of benefit in HIV-positive persons who have already shown resistance to this drug.</brief_summary>
	<brief_title>3TC or No 3TC for HIV With 3TC Resistance</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Be HIV positive Be at least 18 years old. Currently receiving 3TC for HIV infection in conjunction with at least three other antiretroviral drugs. Must have started this regimen at least three months prior to starting this study. A plasma viral load of less than 50 copies/mL on at least two occasions (measured at least 28 days apart immediately prior to screening). Evidence of resistance to 3TC Pregnancy or breastfeeding. Hepatitis B surface antigen (HbsAg) positive at time of screening or with the previous year.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>HIV</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>